Base de dados : MEDLINE
Pesquisa : D27.505.954.427.090 [Categoria DeCS]
Referências encontradas : 1173 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 118 ir para página                         

  1 / 1173 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29342497
[Au] Autor:El-Sayeh HG; Rathbone J; Soares-Weiser K; Bergman H
[Ad] Endereço:Harrogate District Hospital, Tees, Esk & Wear Valleys NHS Foundation Trust, Briary Wing, Lancaster Park Road, Harrogate, North Yorkshire, UK, HG2 7SX.
[Ti] Título:Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.
[So] Source:Cochrane Database Syst Rev;1:CD000458, 2018 01 18.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Tardive dyskinesia (TD) is a disabling movement disorder associated with the prolonged use of antipsychotic medication. Several strategies have been examined in the treatment of TD. Currently, however, there is no clear evidence of the effectiveness of these drugs in TD and they have been associated with many side effects. One particular strategy would be to use pharmaceutical agents which are known to influence the catecholaminergic system at various junctures. OBJECTIVES: 1. To determine the effects of any of the following drugs for antipsychotic-induced TD in people with schizophrenia or other chronic mental illnesses.i. Drugs which influence the noradrenergic system.ii. Dopamine receptor agonists.iii. Dopamine receptor antagonists.iv. Dopamine-depletor drugs.v. Drugs that increase the production or release of dopamine.2. To examine whether any improvement occurred with short periods of intervention (less than 6 weeks) and, if this did occur, whether this effect was maintained at longer periods of follow-up.3. To examine if there was a differential effect for the various compounds.4. To examine whether the use of non-antipsychotic catecholaminergic drugs are most effective in those with more recent onset TD (less than five years). SEARCH METHODS: We retrieved 712 references from searching the Cochrane Schizophrenia Group Trials Register (July 2015 and April 2017). We also inspected references of all identified studies for further trials and contacted authors of trials for additional information. SELECTION CRITERIA: We selected studies if they were randomised controlled trials focusing on people with schizophrenia or other chronic mental illnesses and antipsychotic-induced tardive dyskinesia. We compared the use of catecholaminergic interventions versus placebo, no intervention, or any other intervention for the treatment of antipsychotic-induced tardive dyskinesia. DATA COLLECTION AND ANALYSIS: We independently extracted data from these trials and we estimated risk ratios (RRs) with 95% confidence intervals (CIs). We assumed that people who left the studies early had no improvement. MAIN RESULTS: There are 10 included trials (N = 261) published between 1973 and 2010; eight are new from the 2015 and 2017 update searches. Forty-eight studies are excluded. Participants were mostly chronically mentally ill inpatients in their 50s, and studies were primarily of short (2 to 6 weeks) duration. The overall risk of bias in these studies was unclear, mainly due to poor reporting of allocation concealment and generation of the sequence. Studies were also not clearly blinded and we are unsure if data are incomplete or selectively reported, or if other biases were operating.One small, three-arm trial found that both alpha-methyldopa (N = 20; RR 0.33, 95% CI 0.14 to 0.80; low-quality evidence) and reserpine (N = 20; RR 0.52 95% CI 0.29 to 0.96; low-quality evidence) may lead to a clinically important improvement in tardive dyskinesia symptoms compared with placebo after 2 weeks' treatment, but found no evidence of a difference between alpha-methyldopa and reserpine (N = 20; RR 0.60, 95% CI 0.19 to 1.86; very low quality evidence). Another small trial compared tetrabenazine and haloperidol after 18 weeks' treatment and found no evidence of a difference on clinically important improvement in tardive dyskinesia symptoms (N = 13; RR 0.93, 95% CI 0.45 to 1.95; very low quality evidence). No study reported on adverse events.For remaining outcomes there was no evidence of a difference between any of the interventions: alpha-methyldopa versus placebo for deterioration of tardive dyskinesia symptoms (1 RCT; N = 20; RR 0.33, 95% CI 0.02 to 7.32; very low quality evidence), celiprolol versus placebo for leaving the study early (1 RCT; N = 35; RR 5.28, 95% CI 0.27 to 102.58; very low quality evidence) and quality of life (1 RCT; N = 35; RR 0.87, 95% CI 0.68 to 1.12; very low quality evidence), alpha-methyldopa versus reserpine for deterioration of tardive dyskinesia symptoms (1 RCT; N = 20; not estimable, no reported events; very low quality evidence), reserpine or carbidopa/levodopa versus placebo for deterioration of tardive dyskinesia symptoms (2 RCTs; N = 37; RR 1.18, 95% CI 0.35 to 3.99; very low quality evidence), oxypertine versus placebo for deterioration of mental state (1 RCT; N = 42; RR 2.20, 95% CI 0.22 to 22.45; very low quality evidence), dopaminergic drugs (amantadine, bromocriptine, tiapride, oxypertine, carbidopa/levodopa) versus placebo for leaving the study early (6 RCTs; N = 163; RR 1.29, 95% CI 0.65 to 2.54; very low quality evidence), and tetrabenazine versus haloperidol for deterioration of tardive dyskinesia symptoms (1 RCT; N = 13; RR 1.17, 95% CI 0.09 to 14.92) and leaving the study early (1 RCT; N = 13; RR 0.23, 95% CI 0.01 to 4.00). AUTHORS' CONCLUSIONS: Although there has been a large amount of research in this area, many studies were excluded due to inherent problems in the nature of their cross-over designs. Usually data are not reported before the cross-over and the nature of TD and its likely response to treatments make it imprudent to use this data. The review provides little usable information for service users or providers and more well-designed and well-reported studies are indicated.
[Mh] Termos MeSH primário: Antidiscinéticos/uso terapêutico
Antipsicóticos/efeitos adversos
Discinesia Induzida por Medicamentos/tratamento farmacológico
[Mh] Termos MeSH secundário: Inibidores da Captação Adrenérgica/uso terapêutico
Celiprolol/uso terapêutico
Progressão da Doença
Antagonistas de Dopamina/uso terapêutico
Haloperidol/uso terapêutico
Seres Humanos
Metildopa/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Reserpina/uso terapêutico
Tetrabenazina/uso terapêutico
Cloridrato de Tiapamil/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Adrenergic Uptake Inhibitors); 0 (Anti-Dyskinesia Agents); 0 (Antipsychotic Agents); 0 (Dopamine Antagonists); 56LH93261Y (Methyldopa); 8B1QWR724A (Reserpine); DRB57K47QC (Celiprolol); J6292F8L3D (Haloperidol); V824N2T753 (Tiapamil Hydrochloride); Z9O08YRN8O (Tetrabenazine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD000458.pub3


  2 / 1173 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28797793
[Au] Autor:Strinic D; Belosic Halle Z; Luetic K; Nedic A; Petrovic I; Sucic M; Zivanovic Posilovic G; Balenovic D; Strbe S; Udovicic M; Drmic D; Stupnisek M; Lovric Bencic M; Seiwerth S; Sikiric P
[Ad] Endereço:Departments of Pharmacology & Pathology, Medical Faculty University of Zagreb, Zagreb, Croatia; Faculty of Medicine, J.J. Strossmayer University of Osijek, Osijek, Croatia.
[Ti] Título:BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats.
[So] Source:Life Sci;186:66-79, 2017 Oct 01.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:AIM: Commonly, neuroleptics and prokinetics induce a prolonged QTc interval. In this study, stable gastric pentadecapeptide BPC 157 counteracts the prolongation of the QTc interval in Wistar rats that underwent daily administration of dopamine neuroleptics or prokinetics. Previously, in rats and mice, BPC 157 counteracted neuroleptic-induced catalepsy and gastric ulcers. MAIN METHODS: To counteract neuroleptic- or prokinetic-induced prolongation of the QTc interval, rats were given a BPC 157 regimen once daily over seven days (10µg, 10ng/kg ip) immediately after each administrations of haloperidol (0.625, 6.25, 12.5, and 25.0mg/kg ip), fluphenazine (0.5, 5.0mg/kg ip), clozapine (1.0, 10.0mg/kg ip), quetiapine (1.0, 10.0mg/kg ip), sulpiride (1.6, 16.0mg/kg ip), metoclopramide (2.5, 25.0mg/kg ip) or (1.0, 10.0mg/kg ip). Controls simultaneously received saline (5ml/kg ip). To assess the ECG presentation before and after neuroleptic/prokinetic medication, the assessment was at 1, 2, 3, 4, 5, 10, 15, 20 and 30min (first administration) as well as at 30min, 60min and 24h (first administration and subsequent administrations) and the ECG recording started prior to drug administration. KEY FINDINGS: Since very early, a prolonged QTc interval has been continually noted with haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats as a central common effect not seen with domperidone. Consistent counteraction appears with the stable gastric pentadecapeptide BPC 157. Thus, BPC 157 rapidly and permanently counteracts the QTc prolongation induced by neuroleptics and prokinetics. SIGNIFICANCE: Pentadecapeptide BPC 157 is suited for counteracting a prolonged QT interval.
[Mh] Termos MeSH primário: Antidiscinéticos/efeitos adversos
Antipsicóticos/efeitos adversos
Antagonistas de Dopamina/efeitos adversos
Síndrome do QT Longo/prevenção & controle
Fragmentos de Peptídeos/uso terapêutico
Proteínas/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Relação Dose-Resposta a Droga
Eletrocardiografia
Síndrome do QT Longo/induzido quimicamente
Masculino
Fragmentos de Peptídeos/administração & dosagem
Proteínas/administração & dosagem
Ratos Wistar
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Dyskinesia Agents); 0 (Antipsychotic Agents); 0 (Dopamine Antagonists); 0 (Peptide Fragments); 0 (Proteins); 8ED8NXK95P (BPC 157)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170812
[St] Status:MEDLINE


  3 / 1173 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28389587
[Au] Autor:Maas RPPWM; Wassenberg T; Lin JP; van de Warrenburg BPC; Willemsen MAAP
[Ad] Endereço:From the Department of Neurology (R.P.P.W.M.M., T.W., B.P.C.v.d.W.), Donders Institute for Brain, Cognition, and Behaviour (R.P.P.W.M.M., T.W., B.P.C.v.d.W., M.A.A.P.W.), and Department of Pediatric Neurology (M.A.A.P.W.), Radboud University Medical Center, Nijmegen, the Netherlands; and Complex Mot
[Ti] Título:l-Dopa in dystonia: A modern perspective.
[So] Source:Neurology;88(19):1865-1871, 2017 May 09.
[Is] ISSN:1526-632X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:"Every child exhibiting dystonia merits an l-dopa trial, lest the potentially treatable condition of dopa-responsive dystonia (DRD) is missed" has been a commonly cited and highly conserved adage in movement disorders literature stemming from the 1980s. We here provide a historical perspective on this statement, discuss the current diagnostic and therapeutic applications of l-dopa in everyday neurologic practice, contrast these with its approved indications, and finish with our view on both a diagnostic and therapeutic trial in children and adults with dystonia. In light of the relatively low prevalence of DRDs, the large interindividual variation in the required l-dopa dose, the uncertainty about an adequate trial duration, the substantial advances in knowledge on etiology and pathophysiology of these disorders, and the availability of various state-of-the-art diagnostic tests, we think that a diagnostic l-dopa trial as a first step in the approach of early-onset dystonia (≤25 years) is outdated. Rather, in high-resource countries, we suggest to use l-dopa after biochemical corroboration of a defect in dopamine biosynthesis, in genetically confirmed DRD, or if nigrostriatal degeneration has been demonstrated by nuclear imaging in adult patients presenting with lower limb dystonia. Furthermore, our literature study on the effect of a therapeutic trial to gain symptomatic relief revealed that l-dopa has occasionally proven beneficial in several established "non-DRDs" and may therefore be considered in selected cases of dystonia due to other causes. In summary, we argue against the application of l-dopa in every patient with early-onset dystonia and support a more rational therapeutic use.
[Mh] Termos MeSH primário: Antidiscinéticos/administração & dosagem
Distonia/diagnóstico
Distonia/tratamento farmacológico
Levodopa/administração & dosagem
[Mh] Termos MeSH secundário: Antidiscinéticos/efeitos adversos
Dopamina/biossíntese
Distonia/metabolismo
Seres Humanos
Levodopa/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Dyskinesia Agents); 46627O600J (Levodopa); VTD58H1Z2X (Dopamine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170602
[Lr] Data última revisão:
170602
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170409
[St] Status:MEDLINE
[do] DOI:10.1212/WNL.0000000000003897


  4 / 1173 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28202297
[Au] Autor:Lin CJ; Huang P
[Ad] Endereço:Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
[Ti] Título:Delayed onset diabetic striatopathy: Hemichorea-hemiballism one month after a hyperglycemic episode.
[So] Source:Am J Emerg Med;35(7):1036.e3-1036.e4, 2017 Jul.
[Is] ISSN:1532-8171
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Diabetic striatopathy is an uncommon and life threatening manifestation of diabetes mellitus. It has a tendency to occur in the elderly, female and people of Asian descent. Patients usually present with hemichorea-hemiballism caused by non-ketotic hyperglycemia. However, patients could develop diabetic striatopathy weeks after the hyperglycemic event, even when blood sugar has been well controlled. Herein, we report a case of delayed onset diabetic striatopathy and discuss the importance of detailed history and brain magnetic resonance imaging for making prompt and accurate diagnosis.
[Mh] Termos MeSH primário: Antidiscinéticos/uso terapêutico
Anticonvulsivantes/uso terapêutico
Clonazepam/uso terapêutico
Complicações do Diabetes/fisiopatologia
Discinesias/fisiopatologia
Haloperidol/uso terapêutico
Hiperglicemia/fisiopatologia
Imagem por Ressonância Magnética
[Mh] Termos MeSH secundário: Idoso
Complicações do Diabetes/diagnóstico por imagem
Complicações do Diabetes/tratamento farmacológico
Diagnóstico Diferencial
Discinesias/diagnóstico por imagem
Discinesias/etiologia
Seres Humanos
Hiperglicemia/complicações
Hiperglicemia/tratamento farmacológico
Masculino
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Dyskinesia Agents); 0 (Anticonvulsants); 5PE9FDE8GB (Clonazepam); J6292F8L3D (Haloperidol)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170217
[St] Status:MEDLINE


  5 / 1173 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27874185
[Au] Autor:Freter S; Koller K; Dunbar M; MacKnight C; Rockwood K
[Ad] Endereço:Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
[Ti] Título:Translating Delirium Prevention Strategies for Elderly Adults with Hip Fracture into Routine Clinical Care: A Pragmatic Clinical Trial.
[So] Source:J Am Geriatr Soc;65(3):567-573, 2017 Mar.
[Is] ISSN:1532-5415
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To compare the feasibility (adherence) and effectiveness (prevalence of delirium, length of stay, mortality, discharge site) of delirium-friendly preprinted postoperative orders (PPOs) for individuals with hip fracture, administered by regular orthopedic nurses, with routine postoperative orders. DESIGN: Pragmatic clinical trial to evaluate a quality improvement intervention. SETTING: Tertiary care hospital. PARTICIPANTS: Individuals aged 65 and older admitted for hip fracture repair (N = 283). INTERVENTION: PPOs with delirium-friendly options and doses for nighttime sedation, analgesia, and nausea and attention to catheter removal and bowel movements. MEASUREMENTS: Adherence to PPO was compared with adherence to routine orders. Drug doses were recorded. Presence of delirium was documented using the Confusion Assessment Method and the Mini-Mental State Examination on postoperative Days 1, 3, and 5. Length of stay, discharge site, and in-hospital mortality were recorded. RESULTS: Orthopedic nurses adhered reasonably well with delirium-friendly PPOs. Of 283 participants, 42% developed postoperative delirium, with significantly less delirium in the intervention group (intervention 33%, control 51%, P = .001). The effect of the intervention was stronger in individuals with preexisting dementia (intervention 60%, control 97%, P < .001). Participants with postoperative delirium had longer hospital stays and were more likely to die or be discharged to a nursing home, but there was no significant between-group difference in these outcomes. CONCLUSION: It is possible to introduce delirium-friendly PPOs into routine post-hip fracture care in a representative elderly population including individuals with dementia. Delirium-friendly PPOs executed by regular nursing staff resulted in a significant reduction in postoperative delirium but no difference in other outcomes.
[Mh] Termos MeSH primário: Delírio/prevenção & controle
Fraturas do Quadril/cirurgia
Cuidados Pós-Operatórios/enfermagem
Complicações Pós-Operatórias/prevenção & controle
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Analgésicos/uso terapêutico
Antidiscinéticos/uso terapêutico
Desidratação/prevenção & controle
Delírio/etiologia
Feminino
Haloperidol/uso terapêutico
Seres Humanos
Laxantes/uso terapêutico
Tempo de Internação
Masculino
Enfermagem Ortopédica
Inibidores da Captação de Serotonina/uso terapêutico
Trazodona/uso terapêutico
Cateterismo Urinário/enfermagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRAGMATIC CLINICAL TRIAL
[Nm] Nome de substância:
0 (Analgesics); 0 (Anti-Dyskinesia Agents); 0 (Laxatives); 0 (Serotonin Uptake Inhibitors); J6292F8L3D (Haloperidol); YBK48BXK30 (Trazodone)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161123
[St] Status:MEDLINE
[do] DOI:10.1111/jgs.14568


  6 / 1173 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27855646
[Au] Autor:Alshubaili A; Abou-Al-Shaar H; Santhamoorthy P; Attia H; Bohlega S
[Ad] Endereço:Department of Neurology, Ibn Sina Hospital, Kuwait, Kuwait.
[Ti] Título:Ultrasound-guided botulinum toxin A injection in the treatment of belly dancer's dyskinesia.
[So] Source:BMC Neurol;16(1):226, 2016 Nov 17.
[Is] ISSN:1471-2377
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Belly dancer's dyskinesia is an extremely rare condition. It manifests as semicontinuous, slow, writhing, sinuous abdominal wall movements that are bothersome to the patient. Management of this condition is extremely difficult and challenging. METHODS: We describe four patients with belly dancer's dyskinesia who were treated with Botulinum Toxin A (BTX) injections under ultrasound guidance. RESULTS: All patients underwent the same BTX injection procedure using an aseptic technique under ultrasound guidance. The patients responded well to the BTX injections after an unsatisfactory course of medical treatment. The patients reported complete abolishment of abnormal abdominal movements with no side effects. CONCLUSIONS: We report a cohort of patients with belly dancer dyskinesia treated successfully with BTX injections. Ultrasound guidance for injections increases the accuracy and reduces the risk of the complications. BTX injection under ultrasound guidance is a safe and effective treatment modality that should be employed as a first-line in the management of patients with belly dancer's dyskinesia.
[Mh] Termos MeSH primário: Músculos Abdominais/fisiopatologia
Antidiscinéticos/uso terapêutico
Toxinas Botulínicas Tipo A/uso terapêutico
Discinesias/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Antidiscinéticos/administração & dosagem
Toxinas Botulínicas Tipo A/administração & dosagem
Discinesias/diagnóstico por imagem
Discinesias/patologia
Feminino
Seres Humanos
Injeções Intramusculares
Masculino
Meia-Idade
Estudos Retrospectivos
Resultado do Tratamento
Ultrassonografia de Intervenção
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Dyskinesia Agents); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161119
[St] Status:MEDLINE


  7 / 1173 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27444503
[Au] Autor:Combe L; Abu-Arafeh I
[Ad] Endereço:Department of Paediatrics, Forth Valley Royal Hospital, Larbert, FK5 4WR, UK.
[Ti] Título:Status dystonicus in children: Early recognition and treatment prevent serious complications.
[So] Source:Eur J Paediatr Neurol;20(6):966-970, 2016 Nov.
[Is] ISSN:1532-2130
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This is a retrospective study of all patients presenting to our paediatric unit with status dystonicus (SD) over a period of five years. Anonymous information was collected and a descriptive analysis is made. There were four episodes of SD in three children between 11 and 15 years of age. All children are known to have severe dyskinetic cerebral palsy and presented with an acute or sub-acute deterioration in their symptoms. Symptoms were triggered by infections in three of the four episodes. Early features included frequent and repetitive generalized muscle spasms, poor swallowing, poor sleep, distress and pain. Patients responded to supportive treatment, rehydration, benzodiazepines, baclofen and l-dopa. Intensive care was not necessary in any of the patients and patients made full recovery within 5-14 days. This report shows the value of early recognition and treatment of SD can be successful in preventing serious complications.
[Mh] Termos MeSH primário: Distonia/diagnóstico
Distonia/terapia
[Mh] Termos MeSH secundário: Adolescente
Antidiscinéticos/uso terapêutico
Atetose/etiologia
Atetose/fisiopatologia
Baclofeno/uso terapêutico
Paralisia Cerebral/complicações
Criança
Progressão da Doença
Distonia/etiologia
Feminino
Hidratação
Seres Humanos
Infecção/complicações
Levodopa/uso terapêutico
Masculino
Relaxantes Musculares Centrais/uso terapêutico
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Dyskinesia Agents); 0 (Muscle Relaxants, Central); 46627O600J (Levodopa); H789N3FKE8 (Baclofen)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160723
[St] Status:MEDLINE


  8 / 1173 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27317835
[Au] Autor:Abbassian H; Esmaeili P; Tahamtan M; Aghaei I; Vaziri Z; Sheibani V; Whalley BJ; Shabani M
[Ad] Endereço:Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, 76198-13159, Iran.
[Ti] Título:Cannabinoid receptor agonism suppresses tremor, cognition disturbances and anxiety-like behaviors in a rat model of essential tremor.
[So] Source:Physiol Behav;164(Pt A):314-20, 2016 Oct 01.
[Is] ISSN:1873-507X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cognitive and motor disturbances are serious consequences of tremor induced by motor disorders. Despite a lack of effective clinical treatment, some potential therapeutic agents have been used to alleviate the cognitive symptoms in the animal models of tremor. In the current study, the effects of WIN55, 212-2 (WIN), a cannabinoid receptor (CBR) agonist, on harmaline-induced motor and cognitive impairments were studied. Adult rats were treated with WIN (0.5mg/kg; i.p.) 15min before harmaline administration (10mg/kg; ip) after which exploratory and anxiety related behaviors, and cognitive function were assessed using open-field behavior and shuttle box tests. Rats that received harmaline only exhibited a markedly reduced number of central square entries when compared to harmaline vehicle-treated controls, whereas those treated with WIN and harmaline showed a significant increase in central square entries, compared to harmaline only treated. The passive avoidance memory impairments observed in harmaline treated rats, was reversed somewhat by administration of WIN. The neuroprotective and anxiolytic effects of WIN demonstrated in the current study can be offered cannabinoid receptor (CBR) agonism as a potential neuroprotective agent in the treatment of patients with tremor that manifest mental dysfunctions.
[Mh] Termos MeSH primário: Ansiolíticos/farmacologia
Antidiscinéticos/farmacologia
Benzoxazinas/farmacologia
Agonistas de Receptores de Canabinoides/farmacologia
Tremor Essencial/tratamento farmacológico
Morfolinas/farmacologia
Naftalenos/farmacologia
Nootrópicos/farmacologia
[Mh] Termos MeSH secundário: Animais
Ansiedade/tratamento farmacológico
Ansiedade/fisiopatologia
Aprendizagem da Esquiva/efeitos dos fármacos
Cognição/efeitos dos fármacos
Modelos Animais de Doenças
Tremor Essencial/fisiopatologia
Tremor Essencial/psicologia
Comportamento Exploratório/efeitos dos fármacos
Harmalina
Masculino
Equilíbrio Postural/efeitos dos fármacos
Ratos Endogâmicos WKY
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Anxiety Agents); 0 (Anti-Dyskinesia Agents); 0 (Benzoxazines); 0 (Cannabinoid Receptor Agonists); 0 (Morpholines); 0 (Naphthalenes); 0 (Nootropic Agents); 5H31GI9502 (Win 55212-2); CN58I4TOET (Harmaline)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170614
[Lr] Data última revisão:
170614
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160619
[St] Status:MEDLINE


  9 / 1173 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27261093
[Au] Autor:Heim B; Djamshidian A; Heidbreder A; Stefani A; Zamarian L; Pertl MT; Brandauer E; Delazer M; Seppi K; Poewe W; Högl B
[Ad] Endereço:From the Departments of Neurology (B. Heim, A.D., A.H., A.S., L.Z., M.-T.P., E.B., M.D., K.S., W.P., B. Högl) and Psychology (M.-T.P.), Medical University Innsbruck, Austria; and Department of Molecular Neuroscience and Reta Lila Weston Institute for Neurological Studies (A.D.), University of London
[Ti] Título:Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association?
[So] Source:Neurology;87(1):36-40, 2016 Jul 05.
[Is] ISSN:1526-632X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To assess the frequency of impulse control disorders (ICDs) in patients with restless legs syndrome (RLS) with and without augmentation under dopaminergic therapy in a case-control study. Augmentation and ICDs are both serious complications of dopaminergic treatment of RLS but little is known about possible associations between these drug-induced disorders. METHODS: In total, 58 patients with idiopathic RLS diagnosed according to the International Restless Legs Syndrome Study Group criteria were recruited. Of these, 35 patients had augmentation. The frequency of ICD symptoms was assessed using semi-structural interviews. RESULTS: Demographic variables did not differ between patients with RLS with and without augmentation but those with augmentation took higher dopaminergic medication than patients without augmentation. Twenty-three patients with RLS (39.7%) had ICD symptoms, with 12 patients (20.7%) having definitive ICDs. Patients with augmentation had an increased risk of expressing ICD symptoms (p = 0.007, odds ratio 5.64, 95% confidence interval 1.59-20.02). CONCLUSIONS: Patients with RLS with augmentation have an almost 6-fold increased risk of exhibiting ICD symptoms. This implies that augmentation and ICDs are related and may share a common pathophysiology. Moreover, our results have clinical implications, suggesting that patients with RLS with augmentation should be screened for ICD symptoms.
[Mh] Termos MeSH primário: Transtornos Disruptivos, de Controle do Impulso e da Conduta/complicações
Dopaminérgicos/efeitos adversos
Dopaminérgicos/uso terapêutico
Síndrome das Pernas Inquietas/complicações
Síndrome das Pernas Inquietas/tratamento farmacológico
[Mh] Termos MeSH secundário: Antidiscinéticos/efeitos adversos
Antidiscinéticos/uso terapêutico
Estudos de Casos e Controles
Feminino
Seres Humanos
Entrevista Psicológica
Modelos Logísticos
Masculino
Meia-Idade
Análise Multivariada
Síndrome das Pernas Inquietas/psicologia
Fatores de Risco
Índice de Gravidade de Doença
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Dyskinesia Agents); 0 (Dopamine Agents)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170505
[Lr] Data última revisão:
170505
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160605
[St] Status:MEDLINE
[do] DOI:10.1212/WNL.0000000000002803


  10 / 1173 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27091215
[Au] Autor:Vijayakumar D; Jankovic J
[Ad] Endereço:Department of Neurology, Parkinson's Disease Center and Movement Disorder Clinic, Baylor College of Medicine, 7200 Cambridge, Suite 9A, Houston, TX, 77030-4202, USA.
[Ti] Título:Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.
[So] Source:Drugs;76(7):759-77, 2016 May.
[Is] ISSN:1179-1950
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Dyskinesias encompass a variety of different hyperkinetic phenomenologies, particularly chorea, dystonia, stereotypies, and akathisia. Levodopa-induced dyskinesia (LID) is one of the main types of drug-induced dyskinesia, occurring in patients with Parkinson's disease (PD) who have been treated with levodopa for long time, but this side effect may be encountered even within a few weeks or months after initiation of levodopa therapy. Based on the temporal pattern in relationship to levodopa dosing, LIDs are divided into "peak-dose dyskinesia," "diphasic dyskinesia," and "wearing off" or "off-period" dyskinesia, of which peak-dose dyskinesia is the most common, followed by off-period, and then diphasic dyskinesia. Treatment strategy includes identifying the kind of dyskinesia and tailoring treatment accordingly. Peak-dose dyskinesia is treated mainly by reducing individual doses of levodopa and adding amantadine and dopamine agonists, whereas off-period dystonia often responds to baclofen and botulinum toxin injections. Diphasic dyskinesias, occurring particularly in patients with young-onset PD, are the most difficult to treat. While fractionation of levodopa dosage is the most frequently utilized strategy, many patients require deep brain stimulation to control their troublesome motor fluctuations and LIDs. A variety of emerging (experimental) drugs currently in development promise to provide better control of LIDs and other levodopa-related complications in the near future.
[Mh] Termos MeSH primário: Antidiscinéticos/efeitos adversos
Discinesia Induzida por Medicamentos/terapia
Levodopa/efeitos adversos
[Mh] Termos MeSH secundário: Amantadina/uso terapêutico
Antidiscinéticos/administração & dosagem
Agonistas de Dopamina/uso terapêutico
Seres Humanos
Levodopa/administração & dosagem
Doença de Parkinson/tratamento farmacológico
Qualidade de Vida
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Dyskinesia Agents); 0 (Dopamine Agonists); 46627O600J (Levodopa); BF4C9Z1J53 (Amantadine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171114
[Lr] Data última revisão:
171114
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160420
[St] Status:MEDLINE
[do] DOI:10.1007/s40265-016-0566-3



página 1 de 118 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde